Economic evaluations of antenatal screening programmes often take the additional lifetime costs of care averted, through the detection and subsequent termination of affected fetuses, as the relevant measure of benefit. 1 Indeed, previous evaluations of cystic fibrosis carrier screening programmes have adopted this method.i ' However, measuring benefits purely in terms of averted costs involves a comparison only of the costs of possible courses of action. True benefits, represented by the value of such screening to women or couples, are not evaluated.
Maximum willingness to pay (WTP) has been suggested as an alternative means of measuring the value or benefit of a health care intervention. Individuals are told to imagine that they do have to pay for health care, and then asked what is the maximum amount they would be willing to pay for the intervention that has been described to them. It is left to individuals themselves to judge the relative merits of the benefits which, in the case of antenatal screening programmes, might include such aspects as reassurance, provision of information, or the opportunity to abort should the test prove positive. Thus true benefit is measured and expressed in the same units as cost.
This pilot study aimed at eliciting women's maximum WTP for antenatal cystic fibrosis carrier screening and to assess whether or not WTP was affected by the way in which the test was offered (stepwise or couple testing). With stepwise (disclosure) testing, women attending the clinic are offered a test. If a woman's result is positive, the test is offered to her partner after further counselling. With couple (nondisclosure) testing, a sample is taken from both partners, who are informed of a positive result only if both are found to be carriers."
Subjects, methods, and results
Women attending Aberdeen Maternity Hospital for their antenatal booking visit were randomly allocated to one of the two methods of testing as part of a larger trial described elsewhere." The actual test is the same for both methods -that is, a mouthwash test. Women were told about the test, cystic fibrosis, carrier risk, that not all carriers are detected, and the options available to them if they received a positive result. The explanation was backed up by an information leaflet.
Because of the timing of the decision to perform this study, and the design of the larger screening trial, groups were of unequal size. One hundred and thirty women who had ac-cepted stepwise testing, and 46 who had accepted couple testing, were asked to complete a WTP questionnaire. They were asked to state the maximum amount of money they would be willing to pay for the screening test they had been offered. A questionnaire with suggested WTP values (£0, £1, £2, £4, £8, £10, £12, £16, £20, £30, £50, £75, £100, £100+) was used for all 46 of those offered couple testing, and 81 of those offered stepwise testing. Forty nine who had been offered stepwise testing were given questionnaires with no suggested WTP values.
Response rates were 34(46 (74%) for those offered a couple test and 93(130 (72%) for those offered stepwise testing. There were no significant differences between groups in age, marital status, and social class of respondents and their partners. There was no significant difference between WTP responses elicited with or without suggested WTP values (ratio of means 1'26; 95% confidence interval for ratio 0·91 to 1,76).
Mean WTP (with 95% confidence intervals) was £17.50 (£13.00 to £23.00) for the stepwise group and £22.00 (£14.00 to £36.00) for those offered couple testing. There was no significant difference between WTP values for stepwise or couple testing. The 95% confidence interval for the ratio of these two means is 0·66 to 1·28.
Comment
Maximum WTP as a measure of benefit appeared to be acceptable to our sample, though this was not measured formally. Response rates were good. Only 4(176 women wrote anti-WTP comments on the questionnaire. Maximum WTP allowed us to assess the value placed by women on antenatal carrier testing, and to compare two different approaches to testing. We plan a further study to ascertain whether the lack of difference in WTP for the alternative methods was due to women being asked their WTP only for the test they had, rather than describing each method of testing to a sample of women and asking them their WTP for each one.
Methodological issues regarding questionnaire design and the use of suggested values have been described fully elsewhere." Although no significant difference was found, we urge consistency in the use of suggested or non-suggested values for the purpose of comparability.
WTP is particularly useful for economic assessment of interventions such as screening, where health gain is not the only outcome, and other measures such as quality adjusted life years? are less applicable. Maximum WTP could be useful in the economic evaluation of a wide variety of screening programmes.
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